Adjuvant Intravitreal Bevacizumab Injection for Choroidal and Orbital Metastases of Refractory Invasive Ductal Carcinoma of the Breast

• Published in: Medicina (Kaunas, Lithuania) Vol. 57; no. 5; p. 404
• Main Authors: Lin, I-Hung, Kuo, Bo-I, Liu, Fang-Yu
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22.04.2021; MDPI
• Subjects: Angiogenesis Inhibitors - therapeutic use; bevacizumab; Bevacizumab - therapeutic use; Breast cancer; Cancer therapies; Carcinoma, Ductal - drug therapy; Case Report; Chemotherapy; choroidal metastasis; Drug dosages; Endocrine therapy; Estrogens; Female; Humans; intravitreal injection; Intravitreal Injections; Medical prognosis; Metastasis; Middle Aged; Monoclonal antibodies; orbital metastasis; Patients; Radiation therapy; Targeted cancer therapy; Tomography, Optical Coherence; Tumors; Ultrasonic imaging; Vascular endothelial growth factor; United Kingdom > UK; Switzerland; China; bevacizumab; breast cancer; orbital metastasis; intravitreal injection; choroidal metastasis
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina57050404

The efficacy of combined intravitreal bevacizumab injection with systemic chemotherapy, palliative radiotherapy, and hormonal therapy to treat choroidal and orbital metastases is not known. Herein, we report the case of a 48-year-old woman with systemic chemotherapy-resistant choroidal and orbital metastases of the left eye originating from a stage IV invasive ductal carcinoma of the left breast. We describe the addition of a single intravitreal injection of bevacizumab in addition to treatment with systemic chemotherapy, hormonal therapy, and palliative radiotherapy. The patient's outcome at 6-month follow-up was favorable, as the metastatic lesion reduced in size and visual acuity improved. Combined treatment with intravitreal bevacizumab injection, systemic chemotherapy, palliative radiotherapy, and hormonal therapy can resolve ocular metastatic lesions originating from breast cancers.